M&A Deal Summary |
|
---|---|
Date | 2017-01-23 |
Target | Biotest Pharmaceuticals - US Therapy Business |
Sector | Life Science |
Buyer(s) | ADMA Biologics |
Sellers(s) | Biotest Pharmaceuticals |
Deal Type | Divestiture |
Deal Value | 40M USD |
SEARCH BY
Try For Free 7-Day Free Trial
Category | Company |
---|---|
Founded | 2004 |
Sector | Life Science |
Employees | 624 |
Revenue | 258M USD (2023) |
ADMA Biologics is a late-stage biopharmaceutical company that develops, manufactures, and intends to commercialize specialty plasma-based biologics for the proposed treatment of Immune Deficiencies and the prevention and treatment of certain infectious diseases. ADMA's mission is to develop and commercialize plasma-derived, human immune globulins targeted to niche patient populations for the treatment and prevention of certain infectious diseases. ADMA Biologics was founded in 2004 and is based in Ramsey, New Jersey.
DEAL STATS | # |
---|---|
Overall | 1 of 1 |
Sector (Life Science) | 1 of 1 |
Type (Divestiture) | 1 of 1 |
Country (United States) | 1 of 1 |
Year (2017) | 1 of 1 |
Size (of disclosed) | 1 of 1 |
Category | Company |
---|---|
Founded | 2007 |
Sector | Life Science |
Biotest Pharmaceuticals researches and manufactures biotherapeutic products with a specialization in immunology and hematology. Biotest Pharmaceuticals is a leader in the collection of source plasma and is currently involved in the development of plasma protein products in the field of Primary Immune Deficiency (PID) and various hyperimmune (IG) products which are antibody specific to high titer for treatment of modality.
DEAL STATS | # |
---|---|
Overall | 1 of 1 |
Sector (Life Science) | 1 of 1 |
Type (Divestiture) | 1 of 1 |
Country (United States) | 1 of 1 |
Year (2017) | 1 of 1 |
Size (of disclosed) | 1 of 1 |